Ribociclib Safe, Prolongs PFS Among Older Women With Advanced Breast Cancer

Share this content:
Adding ribociclib to first-line letrozole significantly prolonged progression-free survival and was safe.
Adding ribociclib to first-line letrozole significantly prolonged progression-free survival and was safe.

Adding ribociclib to first-line letrozole significantly prolonged progression-free survival and was safe compared with letrozole alone among women aged 65 years or older with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, according to a study presented at the European Cancer Congress (ECCO) 2017.1

The multicenter, double-blind, phase 3 MONALEESA-2 trial (ClinicalTrials.gov Identifier: NCT01958021) showed that frontline treatment with ribociclib plus letrozole significantly reduced the risk of progression or death by about 44% vs letrozole plus placebo among postmenopausal women with HR-positive, HER2-negative disease (hazard ratio [HR], 0.556; 95% CI, 0.429-0.720).

Because physiologic functioning, comorbidities, and concomitant medications may affect the risk-to-benefit ratio of combination regimens among older patients, researchers conducted a subgroup analysis of MONALEESA-2 to evaluate the efficacy and safety of adding ribociclib for women 65 years or older.

Ribociclib significantly reduced the risk of progression or death by approximately 39% compared with placebo (HR, 0.608; 95% CI, 0.394-0.937). Median progression-free survival was not reached (95% CI, 19.3-not reached) in the ribociclib arm vs 18.4 months (95% CI, 15.0-not reached) in the placebo arm.

RELATED: Triple-negative Breast Cancer: New Strategies for Targeted Therapy

At data cut-off, 60% of patients treated with ribociclib plus letrozole were still receiving treatment compared with 53% of those receiving letrozole alone. In the ribociclib arm, 22% discontinued therapy due to disease progression and 9% as a result of adverse events vs 35% and 3%, respectively, in the placebo arm.

The most common grade 3 to 4 adverse events occurring in significantly more patients treated with ribociclib were neutropenia and leukopenia.

Reference

  1. Sonke GS, Hart LL, Campone M, et al. Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2˗) advanced breast cancer (ABC) in MONALEESA-2. Paper presented at: European Cancer Congress 2017; January 27-30, 2017; Amsterdam, Netherlands.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters